2-Ethyl-4-chlor-thiophen | 89639-44-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 2-Ethyl-4-chlor-thiophen
• 英文别名: 2-Ethyl-4-chlor-thiophen, '3-Chlor-5-ethyl-thiophen'；4-chloro-2-ethyl-thiophene；4-Chloro-2-ethylthiophene
• CAS: 89639-44-1
• 化学式: C₆H₇ClS
• 分子量: 146.641
• InChiKey: NTMXFBWPLJRSAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] TRICYCLIC PYRAZOL AMINE DERIVATIVES<br/>[FR] DÉRIVÉS TRICYCLIQUES DE PYRAZOLAMINE
  申请人：MERCK SERONO SA

  公开号：WO2011058149A1

  公开（公告）日：2011-05-19

  This invention relates to compounds of Formula (I*) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.

  这项发明涉及到 Formula (I*) 的化合物作为 Pi3k 抑制剂，用于治疗自身免疫疾病、炎症性疾病、多发性硬化等疾病，以及癌症等其他疾病。
• [EN] THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS<br/>[FR] THIENO(3,2-D)PYRIMIDINES ET FURANO(3,2-D)PYRIMIDINES ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DES RECEPTEURS PURINERGIQUES
  申请人：VERNALIS RES LTD

  公开号：WO2002055524A1

  公开（公告）日：2002-07-18

  A compound of formula (I), wherein X is S or O; R1 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8; R2 is selected from aryl attached via an unsaturated carbon atom; R3 is selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO2; R4 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8; R5, R6 and R7 are independently selected from H, alkyl and aryl or where R6 and R7 are in an (NR6R7) group, R6 and R7 may be linked to form a heterocyclic group, or where R5, R6 and R7 are in a (CONR5NR6R7) group, R5 and R6 may be linked to form a heterocyclic group; and R8 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, and the use thereof in therapy and in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such a Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or wherein said medicament is for neuroprotection in a subject.

  化合物的化学式为（I），其中X为S或O; R1选自H，烷基，芳基，羟基，烷氧基，芳氧基，硫代烷基，硫代芳基，卤素，CN，COR5，CO2R5，CONR6R7，CONR5NR6R7，NR6R7，NR5CONR6R7，NR5COR6，NR5CO2R8和NR5SO2R8; R2选自通过不饱和碳原子连接的芳基; R3选自H，烷基，羟基，烷氧基，卤素，CN和NO2; R4选自H，烷基，芳基，羟基，烷氧基，芳氧基，硫代烷基，硫代芳基，卤素，CN， ，COR5，CO2R5，CONR6R7，CONR5NR6R7，NR6R7，NR5CONR6R7，NR5COR6，NR5CO2R8和NR5SO2R8; R5，R6和R7独立地选自H，烷基和芳基，或者当R6和R7在（NR6R7）基团中时，R6和R7可以连接形成杂环基团，或者当R5，R6和R7在（CONR5NR6R7）基团中时，R5和R6可以连接形成杂环基团; R8选自烷基和芳基，或其药学上可接受的盐或前药，以及其在治疗中的应用和用于治疗或预防阻断嘌呤受体，特别是腺苷受体，尤其是A2A受体可能有益的紊乱，特别是该紊乱是帕金森病等运动障碍，或该紊乱是抑郁症，认知或记忆障碍，急性或慢性疼痛，ADHD或嗜睡症，或该药物是用于受试者的神经保护。
• THERAPEUTIC AGENT FOR TAUOPATHIES
  申请人：Sumitomo Pharma Co., Ltd.

  公开号：EP4104861A1

  公开（公告）日：2022-12-21

  The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

  本发明提供了一种通过激活电压门控钠通道（Nav）治疗和/或预防tau病的药物。本发明涉及一种治疗和/或预防tau病的药物，其包括Nav激活剂作为活性成分。
• PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT
  申请人：Mitsui Chemicals Agro, Inc.

  公开号：EP3611165A1

  公开（公告）日：2020-02-19

  This is to provide a novel compound capable of treating or preventing plant diseases. The pyridone compounds of the present invention are novel compounds and can treat or prevent plant diseases.

  这是为了提供一种能够治疗或预防植物病害的新型化合物。 本发明的吡啶酮化合物属于新型化合物，可以治疗或预防植物病害。
• Halogen-substituted heterocyclic compound
  申请人：UBE INDUSTRIES, LTD.

  公开号：US10597375B2

  公开（公告）日：2020-03-24

  A novel α-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; R1 is the same or different, and represents a halogen atom, or a C1-C3 alkyl group; R2 represents a hydrogen atom, or a C1-C6 alkyl group; p represents an integer of 0 to 5; V represents CR3 wherein R3 represents a hydrogen atom, an amino group, a nitro group, or a C1-C3 alkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.

  本发明提供了一种新型α-卤素取代的噻吩化合物或其药理学上可接受的盐，该化合物具有强效的LPA受体拮抗剂活性，可用作药物。通式(I)代表的化合物 其中A代表苯基环、噻吩环或异噻唑环；R1相同或不同，代表卤素原子或C1-C3烷基；R2代表氢原子或C1-C6烷基；p代表0～5的整数；V代表CR3，其中R3代表氢原子、氨基、硝基或C1-C3烷氧基，或V代表氮原子；X代表卤素原子或其盐。